GFM
NRIX icon

GF Fund Management’s Nurix Therapeutics NRIX Stock Holding History

GF Fund Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.1K Buy
2,266
+274
+14% +$4.54K ﹤0.01% 441
2025
Q4 		$37.8K Buy
1,992
+347
+21% +$4.99K ﹤0.01% 432
2025
Q3 		$15.2K Sell
1,645
-169
-9% -$1.75K ﹤0.01% 522
2025
Q2 		$20.7K Hold
1,814
– – ﹤0.01% 498
2025
Q1 		$21.6K Buy
1,814
+327
+22% +$5.47K ﹤0.01% 496
2024
Q4 		$28K Buy
+1,487
New +$34.1K ﹤0.01% 440

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

GF Fund Management's NRIX Position: Q1 2026 in Review

GF Fund Management increased its Nurix Therapeutics (NRIX) stake by 14% in Q1 2026, buying an estimated $4.54K and bringing the position to 2,266 shares worth $35.1K. The position accounts for ﹤0.01% of the portfolio, ranked #441.

GF Fund Management first reported a position in NRIX in Q4 2024 and has held it in 6 quarters since. The position peaked at $37.8K in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • GF Fund Management held 2,266 shares of Nurix Therapeutics worth $35.1K as of Q1 2026.
  • GF Fund Management bought 274 Nurix Therapeutics shares in Q1 2026, an estimated $4.54K.
  • Nurix Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #441 holding.
  • GF Fund Management first reported a position in Nurix Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's Nurix Therapeutics position peaked at $37.8K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.